Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors

Trial Profile

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEN 009 (Primary) ; Nivolumab (Primary) ; Pembrolizumab; Poly ICLC
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Malignant melanoma; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Renal cell carcinoma; Skin cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Genocea Biosciences
  • Most Recent Events

    • 09 Nov 2019 Interim results presented in a Genocea Biosciences media release.
    • 09 Nov 2019 According to a Genocea Biosciences media release, data from the study has been presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2019.
    • 05 Nov 2019 According to a Genocea Biosciences media release, data will be presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top